Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 9

Advanced Treatment Options for RA: Exploring the Data

Published on: September 5, 2024

Gordon Lam, MD, Leonard Calabrese, DO, Grace Wright, MD, PhD, Jeffrey A. Sparks, MD, MMSc, Catherine Bakewell, MD

Panelists discuss advanced treatment options for rheumatoid arthritis, focusing on the SELECT-COMPARE trial's head-to-head data of upadacitinib versus adalimumab, the use of upadacitinib in active RA refractory to biologics (SELECT-BEYOND trial), and the remission rates of upadacitinib compared to abatacept (SELECT-CHOICE trial).

EP. 1: Intro and Welcomes

EP. 2: Evolving Goals in Rheumatoid Arthritis Treatment: Defining and Achieving Clinical Remission

EP. 3: Prevalence and Management of Poorly Controlled Rheumatoid Arthritis in Clinical Practice

EP. 4: Complications and Prognostic Factors in Uncontrolled Rheumatoid Arthritis

EP. 5: Evaluating and Adjusting Rheumatoid Arthritis Treatment: Adhering to ACR Guidelines for csDMARDs and Advanced Therapies

EP. 6: Exploring the Discrepancy Between Patient Perception and Disease Activity Assessments

EP. 7: Achieving Low Disease Activity and Remission: Managing Patient Expectations

EP. 8: Guidance on Transitioning from TNFi to Non-TNF Targeted Therapies

Now Viewing

EP. 9: Advanced Treatment Options for RA: Exploring the Data

EP. 10: Guiding Treatment Decisions: The Role of Remission Data and Head-to-Head Comparisons

EP. 11: JAK Inhibitors vs TNF Inhibitors: Effects on Administration, Efficacy, and Safety

EP. 12: JAK Inhibitor Selectivity and Dose-Related Toxicity

Video content above is prompted by the following:

Let’s discuss data of advanced treatment options for rheumatoid arthritis (RA) that may offer a faster pathway to achieving remission.

Please discuss the SELECT-COMPARE trial head-to-head data on upadacitinib vs adalimumab.
Please discuss the use of upadacitinib for active RA refractory to biologic disease-modifying antirheumatic drugs (SELECT-BEYOND trial).
What are the remission rates seen with upadacitinib vs abatacept (SELECT-CHOICE trial)?